References
- McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492:108 - 12; http://dx.doi.org/10.1038/nature11606; PMID: 23051747
- Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 (EZH2) promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 2010; 12:1610 - 8; http://dx.doi.org/10.1158/1541-7786.MCR-10-0398
- Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010; 10:788 - 95; http://dx.doi.org/10.4161/cbt.10.8.12913; PMID: 20686362
- Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 2013; 12; PMID: 23759589
- Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005; 310:306 - 10; http://dx.doi.org/10.1126/science.1118947; PMID: 16224021
- Ferraro A, Mourtzoukou D, Kosmidou V, Avlonitis S, Kontogeorgos G, Zografos G, et al. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells. Int J Biochem Cell Biol 2013; 45:243 - 54; http://dx.doi.org/10.1016/j.biocel.2012.10.009; PMID: 23116973
- Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 2010; 12:1108 - 14; http://dx.doi.org/10.1038/ncb2116; PMID: 20935635
- Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72:2197 - 205; http://dx.doi.org/10.1158/0008-5472.CAN-11-3909; PMID: 22549947